Loading
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
Locametz was approved by the FDA on 23 March 2022, alongside Pluvicto (lutetium-177 vipivotide tetraxetan), with an explicit indication for selecting patients with metastatic castration-resistant prostate cancer for PSMA-directed therapy, as well as for initial staging and biochemical recurrence. The European Commission approved it in December 2022. It is manufactured by Advanced Accelerator Applications, the Novartis radiopharmaceutical unit, and was the first PSMA PET agent approved in the EU. The scan-then-treat pairing is the template for theranostics.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Kit for on-site labelling of gozetotide (PSMA-11) with gallium-68; the resulting tracer images PSMA-expressing prostate cancer and identifies candidates for lutetium-177 PSMA therapy. Connects to PSMA.
1.Locametz (kit for Ga-68 gozetotide) slips into a pocket on PSMA.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 2022 | PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy |
| EU | 2022 | PSMA PET in prostate cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Locametz" OR ABSTRACT:"Locametz" OR TITLE:"kit for Ga-68 gozetotide" OR ABSTRACT:"kit for Ga-68 gozetotide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Locametz (kit for Ga-68 gozetotide), not a curated reading list.
Shares Prostate cancer and the tag test.
Shares PET/CT and the tag test.
Shares Prostate cancer and the tag test.
Shares Prostate cancer and the tag test.
Shares Prostate cancer and the tag test.
Shares VISION, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.